Six-month compliance with antidepressant medication in the treatment of major depressive disorder

被引:54
|
作者
Demyttenaere, Koen [1 ]
Adelin, Albert [2 ]
Patrick, Mesters [3 ]
Walthere, Dewe [3 ]
Katrien, De Bruyckere
Michele, Sangeleer
机构
[1] Univ Hosp Gasthuisberg, Dept Psychiat, B-3000 Louvain, Belgium
[2] Univ Hosp, Dept Biostat, Ghent, Belgium
[3] Eli Lilly Mt St Guibert, European Dev Ctr, Mont St Guibert, Belgium
关键词
antidepressants; compliance; major depressive disorder;
D O I
10.1097/YIC.0b013e3282f1c1d8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The investigation of compliance in patients with major depressive disorder (in drop-outs versus completers and in first episode versus recurrent episode patients). A total of 85 outpatients with major depressive disorder were followed for 6 months. Different dimensions of compliance were investigated: drop-outs versus completers and their medication adherence (with electronic monitoring). General linear mixed models were applied to examine the time courses of adherence. Drop-out rates were higher in younger patients and in patients with a lower initial depression severity. The adherence during 6 months of treatment with selective serotonin reuptake inhibitors was above 80 in 70% of the patients. The adherence decreased by 2.5% per month and decreased more than three times more rapidly in drop-outs (from baseline to time of drop-out). A medical visit resulted in a temporary increase in pill intake. General linear mixed model analysis showed that the predicted outcome was worse in drop-outs than in completers and worse in recurrent episode patients than in first episode patients (the former showing a higher adherence). Adherence decreases with time during 6 months of treatment with antidepressants and is influenced by demographic and clinical variables. Completers show a higher adherence than drop-outs. The outcome was worse in recurrent episode patients than first episode patients although they had a higher adherence.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 50 条
  • [21] Copy number variants and therapeutic response to antidepressant medication in major depressive disorder
    K E Tansey
    J J H Rucker
    D H Kavanagh
    M Guipponi
    N Perroud
    G Bondolfi
    E Domenici
    D M Evans
    J Hauser
    N Henigsberg
    B Jerman
    W Maier
    O Mors
    M O'Donovan
    T J Peters
    A Placentino
    M Rietschel
    D Souery
    K J Aitchison
    I Craig
    A Farmer
    J R Wendland
    A Malafosse
    G Lewis
    S Kapur
    P McGuffin
    R Uher
    The Pharmacogenomics Journal, 2014, 14 : 395 - 399
  • [22] Copy number variants and therapeutic response to antidepressant medication in major depressive disorder
    Tansey, K. E.
    Rucker, J. J. H.
    Kavanagh, D. H.
    Guipponi, M.
    Perroud, N.
    Bondolfi, G.
    Domenici, E.
    Evans, D. M.
    Hausers, J.
    Henigsberg, N.
    Jerman, B.
    Maier, W.
    Mors, O.
    O'Donovan, M.
    Peters, T. J.
    Placentino, A.
    Rietschel, M.
    Souery, D.
    Aitchison, K. J.
    Craig, I.
    Farmer, A.
    Wendland, J. R.
    Malafosse, A.
    Lewis, G.
    Kapur, S.
    McGuffin, P.
    Uher, R.
    PHARMACOGENOMICS JOURNAL, 2014, 14 (04): : 395 - 399
  • [23] A role for genetics in the outcome of antidepressant treatment for major depressive disorder
    Semaka, A.
    CLINICAL GENETICS, 2006, 70 (02) : 110 - U1
  • [24] Sexual dysfunction associated with major depressive disorder and antidepressant treatment
    Clayton, Anita H.
    El Haddad, Saria
    Iluonakhamhe, Josepha-Pearl
    Martinez, Caridad Ponce
    Schuck, Alexandra Elizabeth
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (10) : 1361 - 1374
  • [25] Choosing a second generation antidepressant for treatment of major depressive disorder
    Lester, Helen
    Gilbody, Simon
    BRITISH MEDICAL JOURNAL, 2012, 344
  • [26] Antidepressant treatment in patients with fibromyalgia and comorbid major depressive disorder
    Aguglia, E.
    Aguglia, A.
    Amato, C.
    Petralia, A.
    Ullo, A.
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2009, 66 (06) : 547 - 547
  • [27] Valproate as an antidepressant in major depressive disorder
    Davis, LL
    Kabel, D
    Patel, D
    Choate, AD
    FoslienNash, C
    Gurguis, GNM
    Kramer, GL
    Petty, F
    PSYCHOPHARMACOLOGY BULLETIN, 1996, 32 (04) : 647 - 652
  • [28] Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder
    Dunlop, Boadie W.
    Cole, Steven P.
    Nemeroff, Charles B.
    Mayberg, Helen S.
    Craighead, W. Edward
    JOURNAL OF AFFECTIVE DISORDERS, 2018, 229 : 111 - 119
  • [29] The Neural Effects of Antidepressant Medication on Adults With Major Depressive Disorder: A Meta-Analysis
    Santos, Shay
    Miller, Chris
    BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : S345 - S345
  • [30] DNA methylation and clinical response to antidepressant medication in major depressive disorder: A review and recommendations
    Lisoway, Amanda J.
    Zai, Clement C.
    Tiwari, Arun K.
    Kennedy, James L.
    NEUROSCIENCE LETTERS, 2018, 669 : 14 - 23